Provide Your Patients Improved Vision with MacuMira
Delivering a diagnosis of dry AMD to a patient is hard. Having few options to preserve and protect their vision means letting them leave your clinic without a true resolution.
With MacuMira, you finally have a solution. You can provide real help instead of just hope.
MacuMira is a unique medical device that uses precisely delivered microcurrent to stimulate retinal pigment epithelium (RPE) cells, enhancing mitochondrial activity to support cellular energy production and preserve or improve visual function in people living with dry AMD.
All MacuMira providers receive comprehensive staff training and support from the start and throughout the lifetime of their device. Learn how MacuMira works, how you can equip your clinic with this singular eye disease treatment technology, and how you can gain a new tool to support your patients.

How MacuMira Works
Training Your Team
One of our certified MacuMira trainers will visit you for a half-day of hands-on training. By the end of the day, your team will be ready to provide MacuMira treatment to patients.
Seamless Implementation
MacuMira is designed to integrate smoothly into your existing patient flow. With straightforward protocols and intuitive operation, your team can get up to speed quickly, whether or not they have experience with similar technologies.
Microcurrent Stimulation
MacuMira uses Microcurrent Stimulation to support retinal health. It’s the first and only treatment of its kind for dry AMD, built on technology that has been safely used for decades.
Patented Waveform & Delivery
MacuMira’s patented Microcurrent Stimulation was developed to maximize therapeutic efficacy. Our intuitive user interface is straightforward for a technician to operate.
Retinal Rejuvenation
MacuMira’s stimulation of RPE cells enhances mitochondrial ATP formation, leading to improved cellular function.
Maintaining Results
Patients often have noticeable improvement in visual function after the initial 10-day loading phase (4 x 32-minute sessions). These improvements can be maintained with treatment every 3 months.
Become a MacuMira Provider
Curious about the technology, the device cost, or how you can offer effective dry AMD treatment to your patients? Sign up and we’ll reach out promptly with information. Our mission is to bring innovation in AMD treatment.
MacuMira providers receive comprehensive training from our team to support your successful device implementation. Our mission is to improve the vision and quality of life of people around the world living with dry AMD, and we’d love your help.
How Can MacuMira Improve My Vision & Other Frequently Asked Questions
MacuMira delivers gentle microcurrent energy through your eyelids that stimulates the retina. This is designed to help support your visual function and slow the progression of dry AMD.
Treatments take place at your MacuMira provider’s eye care office, with each session lasting about 32 minutes.
During the treatment, you will be seated or reclined while a headset is placed over your eyes.
Contoured eye cups rest gently on your closed eyelids, delivering microcurrent stimulation to the retina. Many patients find it relaxing enough to fall asleep during treatment.
Some patients experience a mild tingling sensation or brief patterns of light during the session. These are known as phosphenes and are a normal response to the stimulation.
After the session, you can continue with your day as normal with no downtime or restrictions.
Find a MacuMira provider near you with our map tool. If there’s not currently someone in your area, please contact us to be informed of new providers near you.
No, MacuMira treatment isn’t painful, and there are no needles or drugs involved. It’s completely noninvasive.
Some patients feel a slight tingling sensation during the session, but it’s generally very comfortable and well-tolerated.
Most patients report vision improvements within the first 10 days of treatment.
Results vary, but many dry AMD patients describe better contrast (ability to see detail in dim light), sharper reading vision, or less glare sensitivity after the initial 10-day phase of treatment.
Unfortunately, there is currently no cure for dry AMD. MacuMira is not a cure. However, it may help improve functional vision and slow progressive vision loss in people with dry AMD.
Many patients who receive MacuMira begin to notice improvements within the first 10 days during the initial loading phase of treatment.
To maintain those gains, follow-up treatments are typically recommended at least every 3 months. Your optometrist or ophthalmologist will determine the ideal schedule based on your condition and how your vision responds.
Yes, MacuMira can be used alongside your current vision aids and AREDS or AREDS2 supplements. It doesn’t interfere with any other aspects of your eye care.
Yes! MacuMira is a noninvasive treatment that has demonstrated a clinically proven strong safety profile. It has undergone rigorous safety review and licensing by Health Canada and meets the standards required of Class II medical devices.
The stimulation uses microcurrent levels that are incapable of causing muscle contraction and remain well below thresholds associated with discomfort or tissue damage.
No adverse events were reported in the prospective clinical study, and the treatment has now been used in clinical settings with excellent tolerability across thousands of treatment sessions.
Patients typically find the treatment comfortable and easy to complete. It doesn’t involve pills, lasers, injections, or any surgery.
There are currently no other authorized treatments for dry AMD, and nothing else has been shown to improve vision lost to dry AMD.
After diagnosing early stage dry AMD, eye care providers typically recommend lifestyle changes such as healthy eating, quitting smoking, and regular exercise to potentially slow the progression of dry AMD.
For intermediate dry AMD, eye care providers typically recommend dietary supplements, such as AREDS or AREDS2 vitamins. These may slow the progression of the disease, but do not improve vision.
Download the Clinical Trial
The MacuMira clinical trial, published in the International Journal of Retina and Vitreous, found the following:
100%
of patients in the treatment group showed improved vision
48%
of patients improved by at least 10 letters on the ETDRS acuity chart
8.2 ETDRS letters
Average improvement, along with a 25% average increase in ETDRS acuity
0
adverse effects of treatment
100%
of treated patients maintained their vision improvements for the duration of the trial
What’s the Best Thing You Can Do To Prevent Central Vision Loss In Your Patients?
What if vision loss didn’t have to be a guarantee for patients with dry AMD? At MacuMira, we see a future where that’s possible.
For more information on implementing MacuMira, clinical data, patient education strategies, or answers to any other questions, please register using the following form.

Patient Testimonials
“The treatment itself was wonderful; I was not fearful at all. I walked out from my first treatment, and I could see the TVs and the actual printing on the ads.
I couldn’t believe it, I could see across the street, I could see in the other person’s living room. I wanted to be able to drive to places and get to places, and I can do that now.
I felt self-limited because I knew my sight was disintegrating, and now I’m going out. I’m going to my grandkids’ soccer games, and I can see who is who.”
Edith – Alberta
“After my first session, excellent, I took my phone, I could not believe how clear and bright everything was. Just try the treatment, because for me it does wonders.
It was relaxing, no pain whatsoever, none. Everything is just clear!
I do a lot of knitting and crocheting, and now I have no problem; everything is much clearer, much easier. I’m not scared that I’m going to lose my eyesight. I am so much more relaxed.”
Ingrid – Alberta
“I was 10 points away from losing my driver’s license. For me, MacuMira was a godsend, quite frankly.
Not invasive in any way, it was relaxing for me. I didn’t have any problem with it at all. I couldn’t take the chance not to do it, if you know what I mean.
There was a moment after my first treatment where I was able to read street signs a lot more clear. When they had reviewed my vision and I had dropped 20 points, I thought, this is well worth the money spent.
It was emotionally amazing to me to have that clarity again. The biggest change is the lack of anxiety of losing my driver’s license; emotionally, it was very freeing.
I thought if this changes anything, I’m in. If this can change your life and your ability for independence for a little bit longer, it’s worth
the money, every penny! The biggest thing is the feeling of independence, and being able to drive for a lot longer than I thought I was going to be able to. It was a freeing experience, and I’m looking forward to continuing my MacuMira treatments.”
Peter – Alberta
“When I took the headset off, it was so much brighter in the room, I just couldn’t believe it. Everything blurred before, but things were sharper already. I’m very pleased with what I can see. I can even see the hummingbird at my feeder.
It’s brightened me up quite a bit. I am very excited about the rest of my life now. I am just so pleased with this treatment, I am over the moon.
We went out for dinner, and I could read the fortune in my fortune cookie. Before, people’s faces had halos around them. I could not recognize them, now I know who they are.”
Frances – Ontario
“Life before MacuMira was pretty scary for me. Before doing this treatment, I couldn’t see anything on somebody except the outline of their hair.
I had serious heartaches every day, now I don’t
It’s painless, nothing. For 30 minutes? Why wouldn’t anyone do it?
That’s how I knew it was working, because it wasn’t that prominent black mark in the centre of my eye. I’m not full of fear anymore, I’m not worried that I’ll wake up tomorrow and not be able to see.
I found before I was already worried, I was always afraid and scared – and now I’m not. You have to go for it, you got to try it. I’m proof that it’s working.”